Literature DB >> 10669372

Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine.

P Richmond1, E Kaczmarski, R Borrow, J Findlow, S Clark, R McCann, J Hill, M Barker, E Miller.   

Abstract

Widespread use of meningococcal AC polysaccharide (MACP) vaccines has raised concerns about induction of hyporesponsiveness to C polysaccharide. Whether meningococcal C conjugate (MCC) vaccine overcomes any immunologic refractoriness following MACP vaccination in adults was investigated. University students vaccinated 6 months previously with MACP vaccine were randomized to receive MACP or MCC vaccine, and antibody responses were compared with those of previously unvaccinated students receiving MACP or MCC vaccine. In students primed with MACP vaccine, MCC vaccine induced significantly higher IgG and serum bactericidal antibody levels than did a second dose of MACP vaccine. Responses to a second dose of MACP vaccine were significantly lower than to the first dose. Previous receipt of MACP vaccine reduced serum bactericidal antibody but not IgG responses to MCC vaccine compared with those in previously unvaccinated students. This confirms that MACP vaccine induces immunologic hyporesponsiveness to C polysaccharide in adults, but this can be overcome with MCC vaccine. Repeated vaccination with MACP vaccine may be ineffective, and MCC vaccines should provide better long-term protection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10669372     DOI: 10.1086/315284

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

1.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

2.  Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.

Authors:  Jian-li Hu; Hong Tao; Jing-xin Li; Wei-ming Dai; Bin Song; Jin-fang Sun; Pei Liu; Jie Tang; Wen-yu Liu; Shi-yuan Wang; Feng-cai Zhu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Anti-pneumococcal antibody titre measurement: what useful information does it yield?

Authors:  Paul Balmer; Andrew J Cant; Ray Borrow
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

4.  Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.

Authors:  Helen Findlow; Samba Sow; Ray Borrow; Milagritos Tapia; Fadima Cheick Haidara; Adebayo K Akinsola; Olubukola T Idoko; Fatoumata Diallo; Richard Adegbola; Yuxiao Tang; Varsha Parulekar; Helen Chadha; Lesley Mabey; Daniel Holme; Kelly Townsend; Julie Chaumont; F Marc Laforce; Prasad S Kulkarni; Elisa Marchetti; Simonetta Viviani; Musa Hassan-King; Marie-Pierre Preziosi
Journal:  Clin Vaccine Immunol       Date:  2011-07-13

Review 5.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

6.  Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.

Authors:  Jorge Lujan-Zilbermann; Meredith G Warshaw; Paige L Williams; Stephen A Spector; Michael D Decker; Mark J Abzug; Barb Heckman; Adam Manzella; Bill Kabat; Patrick Jean-Philippe; Sharon Nachman; George K Siberry
Journal:  J Pediatr       Date:  2012-05-22       Impact factor: 4.406

7.  Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.

Authors:  George K Siberry; Meredith G Warshaw; Paige L Williams; Stephen A Spector; Michael D Decker; Patrick Jean-Philippe; Ram Yogev; Barbara E Heckman; Adam Manzella; Jhoanna Roa; Sharon Nachman; Jorge Lujan-Zilbermann
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

Review 8.  Review of meningococcal vaccines with updates on immunization in adults.

Authors:  Yorgo C Zahlanie; Moza M Hammadi; Soha T Ghanem; Ghassan S Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

9.  Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.

Authors:  Paul Balmer; Michelle Falconer; Paula McDonald; Nick Andrews; Emily Fuller; Christine Riley; Edward Kaczmarski; Raymond Borrow
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 10.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.